Brugada syndrome risk factors

Brugada syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating Brugada syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Examples of Type I Brugada Syndrome
Chest X Ray
Echocardiography or Ultrasound
Electrophysiologic Studies
Genetic Testing
Treatment
Treatment
Drugs to Avoid
Drugs to Preferably Avoid
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Brugada syndrome risk factors On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Brugada syndrome risk factors All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Brugada syndrome risk factors
CDC on Brugada syndrome risk factors
Brugada syndrome risk factors in the news
Blogs on Brugada syndrome risk factors
Directions to Hospitals Treating Brugada syndrome
Risk calculators and risk factors for Brugada syndrome risk factors

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Risk Factors: Agents and Scenarios that Provoke the Brugada Syndrome Pattern

The electrocardiographic findings of Brugada syndrome are often concealed, but can be unmasked or modulated by a number of drugs and pathophysiological states including:

• Ajmaline (a diagnostic test agent)
• Cocaine
• Fever
• Flecainide (a diagnostic test agent)
• In large studies, a family history of sudden cardiac death among patients with Brugada syndrome does not appear to be a risk factor for sudden cardiac death in siblings.
• Procainamide (a diagnostic test agent)
• Propranolol intoxication
• Sodium channel blockers (a diagnostic test agent)
• Tricyclic antidepressants
• Vagotonic agents that mimic sleep
• α-adrenergic agonists
• β-adrenergic blockers

Risk Statification

• Patients with syncope and an abnormal Type 1 ECG are at higher risk
• Asymptomatic patients at risk can be identified
  • Presence of spontaneous Type 1 ST-segment elevation
  • Characteristics of the S wave
  • Presence of late potentials
  • Inducibility of VT/VF using PES is controversial as a risk factor.